OncoMatch/Clinical Trials/NCT07137819
Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
Is NCT07137819 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Topical treatment for actinic keratosis of face and scalp.
Treatment: Topical treatment — The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
Check if I qualifyExtracted eligibility criteria
Disease stage
Grade: Olsen grade IOlsen grade II (Olsen)
AK lesions of the TA must be clinically typical AK lesions of Olsen grade I and/or grade Olsen grade II.
Prior therapy
Cannot have received: curettage
Curettage for/in a period of 12 weeks
Cannot have received: photodynamic therapy
Photodynamic therapy for/in a period of 12 weeks
Cannot have received: topical inhibitors of Src tyrosine kinase signaling and tubulin polymerization (tirbanibulin)
Topical inhibitors of Src tyrosine kinase signaling and tubulin polymerization (e.g.,Tirbanibulin) for/in a period of 12 weeks
Cannot have received: topical retinoids
Topical retinoids for/in a period of 6 weeks
Cannot have received: topical diclofenac preparations
Topical diclofenac preparations for/in a period of 6 weeks
Cannot have received: topical 5-fluorouracil preparations
Topical 5-fluorouracil preparations for/in a period of 6 weeks
Cannot have received: topical immunomodulators (imiquimod)
Topical immunomodulators (e.g., Imiquimod) for/in a period of 6 weeks
Cannot have received: topical steroids
Topical steroids for/in a period of 4 weeks
Cannot have received: cryo-, thermo- or chemodestruction
Cryo-, thermo- or chemodestruction for/in a period of 4 weeks
Cannot have received: surgical excision
Surgical excision for/in a period of 4 weeks
Cannot have received: systemic immunomodulators or immunosuppressive therapies
Initiation of treatment with the following systemic treatments for any indication within 2 weeks before Baseline: Immunomodulators or immunosuppressive therapies
Cannot have received: systemic diclofenac
Initiation of treatment with Diclofenac within 2 weeks before Baseline
Cannot have received: systemic corticosteroids
Initiation of treatment with Corticosteroids (oral or injectable) within 2 weeks before Baseline
Cannot have received: inhaled corticosteroids (beclomethasone, fluticasone)
Initiation of treatment with Inhaled corticosteroids (>1200 µg/day for beclomethasone, or >600 µg/day for fluticasone) within 2 weeks before Baseline
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify